Rezolute Inc. (RZLT)
NASDAQ: RZLT
· Real-Time Price · USD
3.96
0.20 (5.32%)
At close: May 01, 2025, 3:59 PM
4.02
1.61%
After-hours: May 01, 2025, 05:36 PM EDT
5.32% (1D)
| Bid | 3.89 |
| Market Cap | 321.63M |
| Revenue (ttm) | 58K |
| Net Income (ttm) | -71.13M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -3.22 |
| Forward PE | -3.06 |
| Analyst | Buy |
| Ask | 4 |
| Volume | 781,359 |
| Avg. Volume (20D) | 923,078 |
| Open | 3.76 |
| Previous Close | 3.76 |
| Day's Range | 3.62 - 4.05 |
| 52-Week Range | 2.21 - 6.19 |
| Beta | 0.97 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2013
Employees 64
Stock Exchange NASDAQ
Ticker Symbol RZLT
Website https://www.rezolutebio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 228.70% from the latest price.
Stock Forecasts1 week ago
+27.65%
Rezolute shares are trading higher after the compa...
Unlock content with
Pro Subscription
7 months ago
+22.07%
Rezolute shares are trading higher after the company announced the FDA has removed the partial clinical holds on RZ358.
